Ocugen Inc. - Clinical-Stage Biotechnology

Courageous Innovation. Discover Our Vision → Hear a Retinitis Pigmentosa Patient’s Story from the OCU400 Clinical Trial1 →Explore a Stargardt Patient’s Journey in the OCU410ST Clinical Trial2 →Learn More About a Patient’s Experience with Our Expanded Access Program →

Ocugen is redefining the future of vision through game-changing gene therapies with the potential to address significant, unmet medical needs. Our first-in-class, breakthrough modifier gene therapy platform presents a paradigm shift in treating inherited retinal diseases and blindness diseases affecting millions across the globe.

We are turning purpose into action—delivering hope where none exists.

Hope Begins Here: Patient Journeys →

Guided by compassion and driven by passion, we put patients at the center of everything we do.

Pioneering Biotechnology Leader in Gene Therapies for Blindness Diseases

People across the world live with devastating blindness diseases, waiting for solutions. We believe patients deserve better. We act boldly, think differently, and pursue discoveries that could transform millions of lives.

Ocugen News

02/18/2026

Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results

02/09/2026

Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

01/23/2026

Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock

01/21/2026

Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

01/15/2026

Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

View All

WE ARE OCUGEN

“The promise of helping to transform lives—that’s what drives the work I do at Ocugen. I am proud to be a member of our team of dedicated individuals, collaborating to find solutions to address unmet medical needs, in service for patients.”

— Thais McNeal, Senior Director Government & Industry Affairs, Head Patient Advocacy & Alliance Development

“Healthcare has always been in my DNA and it’s a sector that continues to show us how innovation can change peoples’ lives.”

— Dr. Shankar Musunuri, Chairman, CEO, and co-founder of Ocugen

“We want to offer hope. Not just for vision-related conditions, but for many diseases that seem hopeless.”

— Dr. Arun Upadhyay, Chief Scientific Officer, Head of Research & Development and Medical

“We remind ourselves that nothing is impossible with science; it’s just a matter of figuring things out.”

— Sree Kattala, Research Associate Scientist

Join Our Team “ “

INVESTORS

We are shaping solutions to medical challenges with purpose and agility. Together, we are working to bring more therapeutic options to patients.

Learn About Our Progress

CORPORATE PRESENTATION

Explore how Ocugen is advancing a pipeline built on courage, innovation, and impact.

View Our Corporate Story

Ocugen’s website uses cookies to enhance site navigation and analyze site usage. By clicking “Accept Cookies” or continuing to use this website, you are agreeing to our use of cookies. Click here to see our Cookie Policy

Accept Cookies